Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Bio SB launches antibodies for SARS-CoV-2

April 2021—Bio SB has developed a new panel of SARS-CoV-2 antibodies to identify the COVID-19 virus, its receptors, and its cytokines by immunohistochemistry and immunofluorescence on formalin-fixed, paraffin-embedded biopsies. The antibodies identify ACE2, CD147, and TMPRSS2 receptors and include markers for immune response factors and vascular cells, with the intention to assess the pathological damage caused by COVID-19, cytokine storm syndrome, and coagulopathy, using single and multiplex IHC and immunofluorescence on FFPE tissues.

Bio-Rad enhances InteliQ QC line

April 2021—Bio-Rad Laboratories has enhanced its InteliQ liquid quality controls product line. InteliQ products have improved open-vial stability, and they are now available on Abbott Alinity and Roche Cobas systems.

QIAsphere cloud-based connectivity solution

April 2021—Qiagen launched its QIAsphere cloud-based platform, which will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

Diazyme SARS-CoV-2 IgG semiquantitative test gets EUA

April 2021—Diazyme received FDA emergency use authorization for its Semi-Quantitative DZ-Lite SARS-CoV-2 IgG CLIA test, which runs on the DZ-Lite 3000 Plus chemiluminescence analyzer. The FDA granted Diazyme an EUA for its qualitative DZ-Lite SARS-CoV-2 IgG CLIA test in July and has now authorized the Diazyme IgG assay to be used as a semiquantitative test.

nRichDX unveils Revolution Semi-Automated Workflow

April 2021—nRichDX launched its Revolution Semi-Automated Workflow powered by Eppendorf’s epMotion 5073 instrument for the extraction of cfDNA and ctDNA from plasma and urine for liquid-based assay development. The semiautomated workflow automates the Revolution protocol’s wash and elution steps and is designed to increase yield, sensitivity, and throughput.

Sarstedt specimen transport system

April 2021—Sarstedt introduced its dedicated transportation system for sending specimen tubes to the laboratory, the Tempus600. Sample tubes are placed directly into a sending station and arrive within seconds at a laboratory receiving station for processing. An optional connection module enables tubes to be loaded directly into laboratory automation systems, such as the Sarstedt BL 1200 bulk loader and sorter. The Tempus600 system and pipelines require little space, and installation takes two weeks.

FDA authorizes Cue Health’s OTC COVID-19 test

April 2021—Cue Health has received FDA emergency use authorization for over-the-counter sale of its COVID-19 test. The Cue COVID-19 Test for Home and Over the Counter Use uses a lower nasal swab and provides results in about 20 minutes. The Cue OTC test is authorized for use by symptomatic and asymptomatic individuals, ages two and older.

MARKETPLACE

TRENDING